HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
Background: Zoledronic acid, a bisphosphonate, increases bone mineral density (BMD), which can reduce clinical manifestations in osteogenesis imperfecta. This study investigates the impact of zoledronic acid therapy on the quality of life of pediatric patients with osteogenesis imperfecta. Methods:...
Saved in:
Main Authors: | Tri Wahyu Martanto, Hamzah Rafly Rahman, Patricia Maria Kurniawati |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Airlangga
2023-10-01
|
Series: | Journal Orthopaedi and Traumatology Surabaya |
Subjects: | |
Online Access: | https://e-journal.unair.ac.id/JOINTS/article/view/48362 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
by: Jennifer Walsh, et al.
Published: (2023-11-01) -
Management of Complex Nonunion of Long Bones by Distraction Osteogenesis Using Monorail Fixator
by: Azad Khan, et al.
Published: (2024-01-01) -
Health-related quality of life following bisphosphonate therapy in individuals with Paget’s disease of bone – A study from a teaching hospital in Southern India
by: Fibi K. Ninan, et al.
Published: (2025-01-01) -
Wish Bone Day: Raising Awareness for Osteogenesis Imperfecta – Global and India
by: Yuvaraja Murugan, et al.
Published: (2023-07-01) -
Nelson essentials of pediatrics /
by: Marcdante, Karen J.
Published: (2023)